Centrosomes and myeloma; Aneuploidy and proliferation
Authors:
- 8 September 2009
- journal article
- review article
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 50 (8) , 697-707
Abstract
Multiple myeloma is the second most common hematological malignancy in the United States. The disease is characterized by an accumulation of clonal plasma cells. Clinically, patients present with anemia, lytic bone lesions, hypercalcaemia, or renal impairment. The genome of the malignant plasma cells is extremely unstable and is typically aneuploid and characterized by a complex combination of structure and numerical abnormalities. The basis of the genomic instability underlying myeloma is unclear. In this regard, centrosome amplification is present in about a third of myeloma and may represent a mechanism leading to genomic instability in myeloma. Centrosome amplification is associated with high‐risk features and poor prognosis. Understanding the underlying etiology of centrosome amplification in myeloma may lead to new therapeutic avenues. Environ. Mol. Mutagen., 2009.Keywords
This publication has 77 references indexed in Scilit:
- Multiple myelomaBlood, 2008
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- Targeting aurora kinases as therapy in multiple myelomaBlood, 2007
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- The BRCA1/BARD1 Heterodimer Modulates Ran-Dependent Mitotic Spindle AssemblyCell, 2006
- The molecular classification of multiple myelomaBlood, 2006
- The cellular geography of Aurora kinasesNature Reviews Molecular Cell Biology, 2003
- RHAMM Is a Centrosomal Protein That Interacts with Dynein and Maintains Spindle Pole StabilityMolecular Biology of the Cell, 2003
- Human TPX2 is required for targeting Aurora-A kinase to the spindleJournal of Cell Biology, 2002
- Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpressionOncogene, 2000